INTRODUCTIONIn the United States, 16 420 patients were diagnosed with oropharyngeal squamous cell carcinoma (SCC) in 2015, and the incidence is increasing steadily due to the human papillomavirus (HPV) epidemic. This viral infection of oropharyngeal crypts is the precursor to oncogenic transformation in >60% of oropharyngeal SCC cases, in contrast to the previous paradigm of oropharyngeal SCC induction from tobacco exposure, with distinctive molecular, clinicopathologic, and prognostic characteristics. The HPV‐negative oropharyngeal SCC displays 25% lower 3‐year overall survival (OS; 57% vs 82%; P < .001) compared to HPV‐positive disease, with HPV status being the single most influential prognostic factor for patients with oropharyngeal SCC. Enhanced radiosensitivity and antitumor immune response potentially explain the improved outcomes in HPV‐positive oropharyngeal SCC, which potentially justifies tailoring treatment based on this marker. Indeed, treatment deintensification is currently being tested in HPV‐positive oropharyngeal SCC through elimination/substitution of traditional cisplatin chemosensitization and/or radiation dose reduction.Along with the oropharyngeal SCC epidemiologic shift, advances in surgical technique reintroduced transoral laser microsurgery and introduced transoral robotic surgery (TORS) into the management paradigm. In contrast to the open surgical approach, these minimally invasive surgeries eliminate the mandibulotomy or pharyngotomy that resulted in significant morbidity with traditional surgical approaches. Primary approaches using TORS,
Head & Neck: Journal for the Sciences & Specialties of the Head and Neck – Wiley
Published: Jan 1, 2018
Keywords: ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera